ProCE Banner Activity

CME

Understanding the New Treatment Era of Alternative Therapies for Patients With Hemophilia A

Multimedia
In this on-demand Webcast, Guy A. Young, MD, reviews new therapies available to treat Hemophilia A.

Physicians : maximum of 1.00 AMA PRA Category 1 {Credit}

Released: June 28, 2019

Expiration: June 27, 2020

No longer available for credit.

Share

Faculty

Michael Callaghan

Michael Callaghan, MD

Associate Professor
Department of Hematology
Wayne State University
Hematologist
Division of Hematology/Oncology
Childrens Hospital of Michigan
Detroit, Michigan

Miguel A. Escobar

Miguel A. Escobar, MD

Professor of Medicine and Pediatrics
Division of Hematology
McGovern Medical School
Director
Gulf States Hemophilia and Thrombophilia Center
Houston, Texas

Cindy A. Leissinger

Cindy A. Leissinger, MD

Director
Louisiana Center for Bleeding and Clotting Disorders
New Orleans, Louisiana

Guy Young

Guy Young, MD

Director, Hemostasis and Thrombosis Center
Director, Clinical Coagulation Laboratory
Cancer and Blood Disorders Institute
Children’s Hospital Los Angeles
Professor of Pediatrics
Division of Hematology/Oncology
Department of Pediatrics
University of Southern California Keck School of Medicine
Los Angeles, California

Provided by

Provided by Postgraduate Institute for Medicine
ProCE Banner

Supporters

This activity is supported by an educational grant from

Genentech TEXT Only

Target Audience

This program is intended for hematologists and other healthcare providers who care for patients with hemophilia.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Implement individualized hemophilia management strategies that optimize adherence, outcomes, and utilization of resources
  • Describe novel approaches to treating patients with hemophilia and inhibitors
  • Review the strengths and limitations of outcome measures used currently in hemophilia clinical practice/research and ongoing efforts to develop novel outcome measures that address these common limitations

Disclosure

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Program Director Disclosure

Program Director

Guy Young, MD

Director, Hemostasis and Thrombosis Center
Director, Clinical Coagulation Laboratory
Cancer and Blood Disorders Institute
Children’s Hospital Los Angeles
Professor of Pediatrics
Division of Hematology/Oncology
Department of Pediatrics
University of Southern California Keck School of Medicine
Los Angeles, California

Guy A. Young, MD, has received contracted research support from Genentech, fees for non-CME services from Bioverativ and Genentech, and consulting fees from CSL Behring, Genentech/Roche, Kedrion, Novo Nordisk, Pfizer, and Shire.

Faculty Disclosure

Primary Author

Michael Callaghan, MD

Associate Professor
Department of Hematology
Wayne State University
Hematologist
Division of Hematology/Oncology
Childrens Hospital of Michigan
Detroit, Michigan

Michael Callaghan, MD, has received consulting fees from Bioverativ, Genentech/Roche, Pfizer, and Shire, and has ownership interest in Alnylum.

Miguel A. Escobar, MD

Professor of Medicine and Pediatrics
Division of Hematology
McGovern Medical School
Director
Gulf States Hemophilia and Thrombophilia Center
Houston, Texas

Miguel A. Escobar, MD, has received contracted research support from Genentch, Novo Nordisk, Sanofi, and Takeda, and consulting fees from CSL-Behring, Genentech/Roche, Novo Nordisk, Pfizer, Sanofi, and Takeda/Shire.

Cindy A. Leissinger, MD

Director
Louisiana Center for Bleeding and Clotting Disorders
New Orleans, Louisiana

Cindy A. Leissinger, MD, has received contracted research support from Biomarin and Genentech/Roche, and has received consulting fees from Bayer, CSL Behring, Genetech/Roche, Hemabiologics, Kedrion, Novo Nordisk, Shire/Takeda, Spark and uniQure.

Staff Disclosure

Staff

Taryn Gross, PhD

Director, Program Operations
inPractice Resources, LLC

Krista Marcello,

Associate Managing Editor

Krista Marcello has no real or apparent conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin L. Obholz, PhD, has no real or apparent conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no real or apparent conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Clinical Care Options, LLC. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

The PIM planners and managers have nothing to disclose.

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners.  Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from June 28, 2019, through June 27, 2020:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve participants’ competence in treating patients with hemophilia.